文献速递肝病消化道肿瘤与早癌

一种新型HBx基因型可作为肝细胞癌术前预测因子且不能激活JAK1/STATs通路

A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2019-01-14

研究对284例HBV相关肝细胞癌患者全长HBx基因测序并聚类分析,将其分为HBx-EHBH1、HBx-EHBH2和HBx-EHBH3三种基因型,并在171例验证队列和168例血清队列中验证。HBx-EHBH2(HBx-E2)与更好的无复发生存和总生存相关,且不能促进HCC细胞增殖、不能激活JAK1/STAT3/STAT5通路。

要点

  • 全长HBx基因可分为HBx-EHBH1、HBx-EHBH2和HBx-EHBH3三种基因型。
  • HBx-E2与更好的无复发生存和总生存相关,并可作为BCLC B期HCC肝切除后的预后因素。
  • HBx-E2不能促进HCC细胞和正常肝细胞增殖,也不能激活JAK1/STAT3/STAT5通路。

核心结论

  • 研究识别出一种不能促进HCC细胞增殖的新型HBx基因型,并提示其可作为术前预测BCLC B期HBV相关HCC患者预后的潜在标志物。

研究设计与样本

  • 对284例HBV相关HCC患者(原发队列)全长HBx DNA进行测序和聚类分析以分类基因型,并用171例验证队列和168例血清队列验证结果,通过蛋白微阵列分析探索机制。

主要发现

  • 原发队列中HBx DNA被分为HBx-EHBH1、HBx-EHBH2和HBx-EHBH3三种基因型,HBx-E2提示更好的无复发生存和总生存。
  • HBx-E2与无肝硬化、小肿瘤、单发肿瘤、完整包膜及BCLC A-0期肿瘤显著相关。
  • HBx-E2是BCLC B期HCC患者肝切除术后显著的预后因素。
  • 机制上,HBx-E2不能促进HCC细胞和正常肝细胞增殖,也不能激活JAK1/STAT3/STAT5通路。

临床怎么用

  • 原文结论提示HBx-E2可作为术前预测BCLC B期HBV相关HCC患者预后的潜在标志物。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Genetic variability in the hepatitis B virus X gene (HBx) is frequently observed and is associated with hepatocellular carcinoma (HCC) progression. However, a genotype classification based on the full-length HBx sequence and the impact of genotypes on hepatitis B virus (HBV)-related HCC prognosis remain unclear. We therefore aimed to perform this genotype classification and assess its clinical impact. METHODS: We classified the genotypes of the full-length HBx gene through sequencing and a cluster analysis of HBx DNA from a cohort of patients with HBV-related HCC, which served as the primary cohort (n = 284). Two independent HBV-related HCC cohorts, a validation cohort (n = 171) and a serum cohort (n = 168), were used to verify the results. Protein microarray assay analysis was performed to explore the underlying mechanism. RESULTS: In the primary cohort, the HBx DNA was classified into 3 genotypes: HBx-EHBH1, HBx-EHBH2, and HBx-EHBH3. HBx-EHBH2 (HBx-E2) indicated better recurrence-free survival and overall survival for patients with HCC. HBx-E2 was significantly correlated with the absence of liver cirrhosis, a small tumor size, a solitary tumor, complete encapsulation and Barcelona Clinic Liver Cancer (BCLC) stage A-0 tumors. Additionally, HBx-E2 served as a significant prognostic factor for patients with BCLC stage B HCC after hepatectomy. Mechanistically, HBx-E2 is unable to promote proliferation in HCC cells and normal hepatocytes. It also fails to activate the Janus kinase 1 (JAK1)/signal transducer and activator of transcription 3 (STAT3)/STAT5 pathway. CONCLUSION: Our study identifies a novel HBx genotype that is unable to promote the proliferation of HCC cells and suggests a potential marker to preoperatively predict the prognosis of patients with BCLC stage B, HBV-associated, HCC. LAY SUMMARY: We classified a novel genotype of the full-length hepatitis B virus X gene (HBx), HBx-E2. This genotype was identified in tumor and nontumor tissues from patients with hepatitis B virus-related hepatocellular carcinoma. HBx-E2 could preoperatively predict the prognosis of patients with intermediate stage hepatocellular carcinoma, after resection.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Xu QG, Yuan SX, Tao QF, et al. A novel HBx genotype serves as a preoperative predictor and fails to activate the JAK1/STATs pathway in hepatocellular carcinoma. J Hepatol. 2019. PMID: 30654066. doi:10.1016/j.jhep.2019.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。